Tag: antidiabetics industry share

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Antidiabetics Industry Compare Between 2025 And 2029?

The antidiabetics market has seen substantial expansion recently. It is projected to increase from $76.03 billion in 2024 to $84.07 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 10.6%. This historical growth can be primarily attributed to rising global diabetes prevalence, advancements in drug development, increased awareness and diagnosis, supportive government policies, a growing geriatric population, sedentary lifestyles, and increasing healthcare expenditure.

The market for antidiabetics is projected to experience swift expansion over the coming years. This market is forecast to reach $127.48 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 11.0%. Key factors driving this projected growth include the rising incidence of diabetes, heightened awareness and improved diagnosis, increased spending on healthcare, the growing elderly demographic, and various government health programs and policies. Significant developments anticipated during this forecast timeframe encompass the proliferation of GLP-1 receptor agonists and SGLT2 inhibitors, the broadening of biologics and biosimilars, a greater emphasis on preventive health measures, expansion in developing markets, and enhanced technological integration.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18225&type=smp

What Are The Drivers Pushing New Developments In The Antidiabetics Market?

The escalating prevalence of lifestyle-related health problems is anticipated to boost the expansion of the antidiabetics market moving forward. These conditions are health issues triggered or worsened by behaviors such as an unhealthy diet, insufficient physical activity, smoking, and excessive alcohol consumption. The occurrence of lifestyle-related conditions is increasing due to poor nutritional habits, sedentary lifestyles, and heightened stress levels. Antidiabetic medications can assist in managing lifestyle-related ailments like obesity and metabolic syndrome by enhancing insulin sensitivity and regulating blood sugar levels. For example, in March 2022, the World Health Organization, an intergovernmental entity based in Switzerland, reported that roughly 1 billion people across the globe, including 650 million adults, 340 million teenagers, and 39 million children, were living with obesity. This figure continues its upward trend. Projections indicate that by 2025, an estimated 167 million adults and children will face health complications stemming from being overweight or obese. Thus, the increasing incidence of lifestyle-related conditions is fueling the antidiabetics market.

How Is The Antidiabetics Market Classified Into Different Segments?

The antidiabeticsmarket covered in this report is segmented –

1) By Drug Class: Insulin; GLP-1 Receptor Agonists; DPP- 4 Inhibitors; SGLT2 Inhibitors; Other Drug Classes,

2) By Diabetes Type: Type 1; Type 2

3) By Patient Population: Antidiabetics For Pediatrics; Antidiabetics For Adults; Antidiabetics For Geriatrics

4) By Route Of Administration: Antidiabetics Administration Through Insulin Syringes Or Insulin Pens; Antidiabetics Administration Through Insulin Pumps; Intravenous Antidiabetics Infusion; Oral Antidiabetics Administration; Other Routes Of Antidiabetics Administration

5) By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Retail Pharmacies

Subsegments:

1) By Insulin: Rapid-Acting Insulin; Short-Acting Insulin; Intermediate-Acting Insulin; Long-Acting Insulin; Premixed Insulin

2) By GLP-1 Receptor Agonists: Exenatide; Liraglutide; Dulaglutide; Semaglutide; Lixisenatide

3) By DPP-4 Inhibitors: Sitagliptin; Saxagliptin; Linagliptin; Alogliptin

4) By SGLT2 Inhibitors: Canagliflozin; Dapagliflozin; Empagliflozin; Ertugliflozin

5) By Other Drug Classes: Sulfonylureas; Thiazolidinediones (TZDs); Alpha-Glucosidase Inhibitors; Meglitinides; GLP-1/Insulin Combination Therapy

What Trends Are Redefining The Antidiabetics Market Dynamics?

Major companies within the antidiabetics market are actively developing advanced products, such as anti-diabetic biosimilars, aiming to improve glycemic control, lessen the risk of cardiovascular events, and provide more effective treatment options for individuals with diabetes. An anti-diabetic biosimilar is a medication biologically similar to an already approved reference drug for diabetes treatment, offering comparable safety, effectiveness, and quality. For example, in January 2024, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, introduced the first biosimilar of Liraglutide, an anti-diabetic drug. This biosimilar, launched as Lirafit, enhances glycemic control in adults diagnosed with type 2 diabetes mellitus. Clinical trials have indicated its effectiveness in lowering glycemic parameters, assisting with weight loss, and boosting cardiovascular safety. As a GLP-1 receptor agonist, it stimulates glucose-dependent insulin secretion and decreases inappropriate glucagon secretion. It has received global approval for managing type 2 diabetes in adults.

Which Leading Players Are Enhancing Their Antidiabetics Market Presence Worldwide?

Major companies operating in the antidiabetics market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen, Vertex Pharmaceuticals Incorporated, Servier Laboratories, Sun Pharmaceutical Industries Limited, Cipla Limited, Dr. Reddy’s Laboratories, Lupin Limited, Torrent Pharmaceuticals Ltd, Biocon Limited, Glenmark Pharmaceuticals Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

What Regional Growth Trends Are Shaping The Antidiabetics Market Outlook?

North America was the largest region in the antidiabetics market in 2024. The regions covered in the antidiabetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Antidiabetics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=18225&type=smp

Browse Through More Reports Similar to the Global Antidiabetics Market 2025, By The Business Research Company

Anti Hypertensive Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Antithrombotic Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/antithrombotic-drugs-market

Anti Asthmatics And Copd Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the antidiabetics industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Antidiabetics Market Size Shifted, And What Is the Outlook Through 2034?

In recent times, the antidiabetics market has witnessed substantial expansion. It is anticipated to rise from the 2024 market value of $76.03 billion to $84.84 billion in 2025 with a compound annual growth rate (CAGR) of 11.6%. Factors attributing to this increase during the historic period include the surge in global diabetes incidence, advances in medication development, heightened awareness, wider diagnosis, beneficial governmental strategies, an aging population, inactive lifestyles, and escalating healthcare spending.

The market size for antidiabetics is anticipated to experience a substantial surge in the upcoming years, escalating to $130.12 billion by 2029, with a compound annual growth rate (CAGR) of 11.3%. Factors contributing to this expansion in the predicted period include the rising incidents of diabetes, enhanced awareness and diagnosis, growth in healthcare spending, the increase in the elderly population, and initiatives and health policies implemented by the government. Key trends during this forecast period encompass the expansion of GLP-1 receptor agonists and SGLT2 inhibitors, proliferation of biologics and biosimilars, emphasis on preventive healthcare, growth in emerging markets, and integration of advanced technology.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18225&type=smp

Which Factors and External Forces Are Driving Demand in the Antidiabetics Market?

The growth of the antidiabetics market is forecasted to be propelled by the escalating prevalence of conditions related to unhealthy lifestyles. Lifestyle-associated health issues stem from or are worsened by harmful habits such as inadequate diet, sedentary behavior, smoking, and heavy drinking. With unhealthy diets, lack of physical activity, and heightened stress levels on the rise, so is the prevalence of these lifestyle-related conditions. Antidiabetic drugs can aid in managing these lifestyle-related disorders, such as obesity and metabolic syndrome, by enhancing insulin sensitivity and regulating glucose levels in the blood. For example, the World Health Organization, headquartered in Switzerland, reported in March 2022 that about 1 billion people globally, including 650 million adults, 340 million teens, and 39 million children, are obese. This figure continues to climb. By 2025, it’s projected that 167 million adults and children will experience health issues due to overweight or obesity. Therefore, the escalating prevalence of lifestyle-implicated conditions is fueling the expansion of the antidiabetic market.

Which Segments in the Antidiabetics Offer the Most Growth?

The antidiabetics market covered in this report is segmented –

1) By Drug Class: Insulin, GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors, Other Drug Classes,

2) By Diabetes Type: Type 1, Type 2

3) By Patient Population: Antidiabetics For Pediatrics, Antidiabetics For Adults, Antidiabetics For Geriatrics

4) By Route Of Administration: Antidiabetics Administration Through Insulin Syringes Or Insulin Pens, Antidiabetics Administration Through Insulin Pumps, Intravenous Antidiabetics Infusion, Oral Antidiabetics Administration, Other Routes Of Antidiabetics Administration

5) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin

2) By GLP-1 Receptor Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide

3) By DPP-4 Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin

4) By SGLT2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin

5) By Other Drug Classes: Sulfonylureas, Thiazolidinediones (TZDs), Alpha-Glucosidase Inhibitors, Meglitinides, GLP-1/Insulin Combination Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=18225&type=smp

What Are the Fastest-Growing Geographies in the Antidiabetics Market?

North America was the largest region in the antidiabetics market in 2023. The regions covered in the antidiabetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Antidiabetics Market?

Leading firms in the antidiabetics market are introducing innovative products like anti-diabetic biosimilars intended to enhance glycemic regulation, mitigate the probability of cardiovascular incidents, and provide more efficient treatment solutions for people suffering from diabetes. An anti-diabetic biosimilar is a bioequivalent drug to a previously sanctioned reference product used in diabetes treatment with similar safety, efficacy, and quality. For example, Glenmark Pharmaceuticals Limited, a pharmaceutical firm based in India, introduced the first biosimilar of Liraglutide, a medication for diabetes, in January 2024. The biosimilar version of the Liraglutide anti-diabetic drug, marketed as Lirafit, ameliorates glycemic management in adults diagnosed with type 2 diabetes mellitus. Clinical studies indicate that it decreases glycemic parameters, assists in weight reduction, and promotes cardiovascular safety. As a GLP-1 receptor stimulant, it heightens glucose-responsive insulin secretion and curbs improper glucagon secretion. It has worldwide approval for controlling type 2 diabetes in adults.

View the full report here:

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

What Are the Key Elements That Define the Antidiabetics Market?

Antidiabetics are a class of medications used to treat diabetes mellitus, a condition characterized by high blood glucose levels. These medications help control blood sugar levels in various ways, depending on the type of diabetes and the mechanism of the drug. Antidiabetics manage blood sugar levels, reduce complications, improve health outcomes, enhance metabolic control and insulin sensitivity, offer customized treatment options, and provide additional benefits such as weight management and cardiovascular protection.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18225

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Drivers Are Shaping the Growth and Development of theAntidiabetics Market?

An increase in health conditions related to lifestyle habits is anticipated to spur the expansion of the antidiabetics market. These lifestyle-related illnesses arise or are accentuated by behaviors such as unhealthy eating habits, insufficient physical activity, smoking, and excessive consumption of alcohol. The prevalence of these health conditions is escalating due to inadequate diet, lack of regular exercise, and heightened stress levels. Antidiabetic drugs can aid in regulating conditions linked to lifestyle, such as obesity and metabolic syndrome, by enhancing insulin sensitivity and managing blood sugar. For example, in March 2022, the World Health Organization, a Switzerland-based international organization, disclosed that about 1 billion people globally – including 650 million adults, 340 million teenagers, and 39 million children – were obese and this statistic is on an upward trend. It is projected that by 2025, approximately 167 million adults and children will face health issues due to being overweight or obese. Thus, the escalating incidence of lifestyle-related health issues is propelling the growth of the antidiabetic market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18225&type=smp

#What Long-Term Growth Rate is Expected for theAntidiabetics Market Between 2025 and 2034?

The expansion of the antidiabetics market has been swift in recent years, with predictions indicating a rise from $76.03 billion in 2024 to $84.84 billion in 2025, marking a compound annual growth rate (CAGR) of 11.6%. The observed growth in the previous years is ascribed to numerous factors including an upsurge in global diabetic cases, progress in the development of medicines, enhanced levels of awareness and diagnosis, government policies supporting these developments, a rising elderly population, inactive lifestyles, and growing healthcare spending.

In the coming years, the antidiabetics market is anticipated to experience accelerated growth, reaching a size of $130.12 billion by 2029, with a compound annual growth rate (CAGR) of 11.3%. This expected expansion during the forecast period credits to factors such as the rising incidence of diabetes, heightened awareness and diagnosis, growing healthcare costs, an increasing older population, and government-led healthcare initiatives and policies. The time frame also foresees key growth trends such as the emergence of GLP-1 receptor agonists and SGLT2 inhibitors, an upward surge in biologics and biosimilar products, a concentrated emphasis on preventive healthcare, developing market expansion, and the incorporation of technology.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18225

Which Cutting-Edge Market Trends Are Expected to Drive theAntidiabetics Market’s Growth?

Leading organizations in the antidiabetics industry are introducing innovative products like the anti-diabetic biosimilar. These advanced products are designed for better glycemic management, decreased risk of cardiac incidents, and providing superior therapy alternatives for diabetes patients. An anti-diabetic biosimilar is a medication that is biologically equivalent to an already approved reference drug for diabetes treatment. This drug ensures similar safety, effectiveness, and quality. For example, in January 2024, Glenmark Pharmaceuticals Limited, a company based in India, introduced the initial biosimilar of Liraglutide, a drug used to treat diabetes. This Liraglutide biosimilar, launched under the brand name Lirafit, assists in glycemic control in patients with type 2 diabetes mellitus. Clinical studies prove that it reduces glycemic parameters, aids in weight reduction, and improves cardiovascular safety. As a GLP-1 receptor agonist, it promotes glucose-dependent insulin secretion and minimizes inappropriate glucagon secretion. It has global approval for the management of type 2 diabetes in adults.

What Are the Leading Market Players Impacting theAntidiabetics Market’s Growth Trend?

Major companies operating in the antidiabetics market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen, Vertex Pharmaceuticals Incorporated, Servier Laboratories, Sun Pharmaceutical Industries Limited, Cipla Limited, Dr. Reddy’s Laboratories, Lupin Limited, Torrent Pharmaceuticals Ltd, Biocon Limited, Glenmark Pharmaceuticals Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

How Are the Key Segments of the Antidiabetics Market Driving Opportunities and Innovations?

The antidiabetics market covered in this report is segmented –

1) By Drug Class: Insulin, GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors, Other Drug Classes,

2) By Diabetes Type: Type 1, Type 2

3) By Patient Population: Antidiabetics For Pediatrics, Antidiabetics For Adults, Antidiabetics For Geriatrics

4) By Route Of Administration: Antidiabetics Administration Through Insulin Syringes Or Insulin Pens, Antidiabetics Administration Through Insulin Pumps, Intravenous Antidiabetics Infusion, Oral Antidiabetics Administration, Other Routes Of Antidiabetics Administration

5) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin

2) By GLP-1 Receptor Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide

3) By DPP-4 Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin

4) By SGLT2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin

5) By Other Drug Classes: Sulfonylureas, Thiazolidinediones (TZDs), Alpha-Glucosidase Inhibitors, Meglitinides, GLP-1/Insulin Combination Therapy

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=18225&type=smp

What Regions Are At the Forefront of #What Drivers Are Shaping the Growth and Development of theAntidiabetics Market?# Market Expansion?

North America was the largest region in the antidiabetics market in 2023. The regions covered in the antidiabetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Antidiabetics Market 2025, By The Business Research Company:

Anti-Hypertensive Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Anti-Thyroid Drugs Global Market Report 2019

https://www.thebusinessresearchcompany.com/report/antithyroid-drugs-global-market-report

Antithrombotic Drugs Global Market Opportunities And Strategies To 2030

https://www.thebusinessresearchcompany.com/report/antithrombotic-drugs-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the antidiabetics market size evolved in recent years?

The antidiabetics market has seen rapid growth in recent years. It will grow from $76.03 billion in 2024 to $84.84 billion in 2025, with a compound annual growth rate (CAGR) of 11.6%. This expansion is driven by the rising global prevalence of diabetes, advances in drug development, increased awareness and diagnosis, supportive government policies, an aging population, sedentary lifestyles, and rising healthcare costs.

What are the predictions for the antidiabetics market size in the coming years?

The antidiabetics market is projected to grow quickly, reaching $130.12 billion by 2029 at a CAGR of 11.3%. This growth is attributed to the rising prevalence of diabetes, better awareness and diagnosis, increasing healthcare spending, a growing elderly population, and supportive government policies. Trends in the market include the expansion of GLP-1 receptor agonists and SGLT2 inhibitors, the growth of biologics and biosimilars, a focus on preventive healthcare, emerging markets, and technological integration.

Get your antidiabetics market report here!

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

What key factors are fueling the growth of the antidiabetics market?

The rising incidence of lifestyle-related conditions is expected to fuel the growth of the antidiabetics market. Lifestyle-related conditions, such as obesity and metabolic syndrome, are increasing due to poor diet, lack of exercise, and stress. Antidiabetic medications help manage these conditions by improving insulin sensitivity and controlling blood sugar levels. In 2022, the World Health Organization reported that obesity is rising globally, with an estimated 167 million adults and children expected to suffer from the health consequences of obesity by 2025. This trend is driving the antidiabetic market.

How is the global antidiabetics market divided into key segments?

The antidiabetics market covered in this report is segmented –

1) By Drug Class: Insulin, GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors, Other Drug Classes,

2) By Diabetes Type: Type 1, Type 2

3) By Patient Population: Antidiabetics For Pediatrics, Antidiabetics For Adults, Antidiabetics For Geriatrics

4) By Route Of Administration: Antidiabetics Administration Through Insulin Syringes Or Insulin Pens, Antidiabetics Administration Through Insulin Pumps, Intravenous Antidiabetics Infusion, Oral Antidiabetics Administration, Other Routes Of Antidiabetics Administration

5) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin

2) By GLP-1 Receptor Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide

3) By DPP-4 Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin

4) By SGLT2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin

5) By Other Drug Classes: Sulfonylureas, Thiazolidinediones (TZDs), Alpha-Glucosidase Inhibitors, Meglitinides, GLP-1/Insulin Combination Therapy

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18225&type=smp

Who are the key firms paving the way for growth in the antidiabetics market?

Major companies operating in the antidiabetics market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen, Vertex Pharmaceuticals Incorporated, Servier Laboratories, Sun Pharmaceutical Industries Limited, Cipla Limited, Dr. Reddy’s Laboratories, Lupin Limited, Torrent Pharmaceuticals Ltd, Biocon Limited, Glenmark Pharmaceuticals Ltd.

Which trends are expected to transform the antidiabetics market?

Companies in the antidiabetics market are developing biosimilars to offer better treatment options for diabetes. For example, in January 2024, Glenmark Pharmaceuticals launched Lirafit, a biosimilar of the anti-diabetic drug Liraglutide. Clinical trials show it helps in glycemic control, weight loss, and improving cardiovascular safety for adults with type 2 diabetes.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18225

What regions are contributing significantly to the growth of the antidiabetics market?

North America was the largest region in the antidiabetics market in 2023. The regions covered in the antidiabetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Anti-Hypertensive Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Anti-Thyroid Drugs Global Market Report 2019

https://www.thebusinessresearchcompany.com/report/antithyroid-drugs-global-market-report

Antithrombotic Drugs Global Market Opportunities And Strategies To 2030

https://www.thebusinessresearchcompany.com/report/antithrombotic-drugs-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What Growth Rate is Predicted for the Antidiabetics Market for 2024-2033?

The antidiabetics market has grown significantly, rising from $68.32 billion in 2023 to $76.03 billion in 2024, with a CAGR of 11.3%. Growth drivers include the increasing global prevalence of diabetes, advancements in drug development, greater awareness and diagnosis, government support, and rising healthcare expenditures.

The antidiabetics market is set to experience rapid growth, anticipated to reach $117.04 billion by 2028 at a CAGR of 11.4%. This growth is driven by the rising prevalence of diabetes, increased awareness and diagnosis, higher healthcare spending, an expanding geriatric population, and supportive government initiatives. Key trends include growth in GLP-1 receptor agonists and SGLT2 inhibitors, the expansion of biologics and biosimilars, a focus on preventive healthcare, growth in emerging markets, and technological integration.

What Drivers Are Enhancing the Antidiabetics Market’s Growth?

The antidiabetics market is anticipated to grow due to the rising prevalence of lifestyle-related conditions. These health issues stem from behaviors such as poor diet, lack of exercise, smoking, and excessive alcohol consumption. The growing incidence of lifestyle-related conditions is linked to unhealthy dietary habits, sedentary lifestyles, and increased stress levels. Antidiabetic medications can help manage these conditions, such as obesity and metabolic syndrome, by enhancing insulin sensitivity and regulating blood sugar levels.

Claim Your Free Sample of the Global Antidiabetics Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=18225&type=smp

What Segments Are Central to the Antidiabetics Market?

The antidiabetics market covered in this report is segmented –

1) By Drug Class: Insulin, GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors, Other Drug Classes,
2) By Diabetes Type: Type 1, Type 2
3) By Patient Population: Antidiabetics For Pediatrics, Antidiabetics For Adults, Antidiabetics For Geriatrics
4) By Route Of Administration: Antidiabetics Administration Through Insulin Syringes Or Insulin Pens, Antidiabetics Administration Through Insulin Pumps, Intravenous Antidiabetics Infusion, Oral Antidiabetics Administration, Other Routes Of Antidiabetics Administration
5) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

What Emerging Trends Are Influencing Antidiabetics Industry Dynamics?

Major companies in the antidiabetics market are introducing advanced products like anti-diabetic biosimilars. Glenmark Pharmaceuticals launched Lirafit in January 2024, the first biosimilar of Liraglutide for type 2 diabetes management.

Order Now for Fast Delivery of Your Antidiabetics Market Report!

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Which Geographic Locations Are Critical to the Growth of the Antidiabetics Market?

North America was the largest region in the antidiabetics market in 2023. The regions covered in the antidiabetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Antidiabetics Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the antidiabetics market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Antidiabetics Market Include

1. Antidiabetics Market Executive Summary
2. Antidiabetics Market Segments
3. Antidiabetics Market Size And Template Market Growth Rate
4.  Key Antidiabetics Market Trends
5. Major Antidiabetics Market Drivers
……
25. Key Mergers And Acquisitions In The Antidiabetics Market
26. Top Antidiabetics Companies
27. Antidiabetics Market Opportunities And Strategies
28. Antidiabetics Market, Conclusions And Recommendations
29. Appendix

Discover Related Reports by The Business Research Company:

Ischemic Heart Disease (IHD) Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

Anti-Asthmatics And COPD Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

Vascular Closure Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/vascular-closure-devices-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

The antidiabetics market has experienced rapid growth in recent years, increasing from $68.32 billion in 2023 to $76.03 billion in 2024, with a compound annual growth rate (CAGR) of 11.3%. Key factors driving this growth include the rising global prevalence of diabetes, advancements in drug development, increased awareness and diagnosis, supportive government policies, a growing geriatric population, and the rise of sedentary lifestyles. The antidiabetics market is expected to continue its expansion, reaching $117.04 billion by 2028, with a CAGR of 11.4%. This forecasted growth is driven by the increasing prevalence of diabetes, greater awareness and diagnosis rates, rising healthcare expenditure, expanding geriatric populations, and government initiatives and health policies. Major trends in the forecast period include the growth of GLP-1 receptor agonists, SGLT2 inhibitors, biologics, biosimilars, a focus on preventive healthcare, emerging market expansion, and technological integration.

The rising incidence of lifestyle-related conditions is expected to propel the growth of the antidiabetics market going forward. Lifestyle-related conditions are health issues caused or exacerbated by behaviors such as poor diet, lack of exercise, smoking, and excessive alcohol consumption. The incidence of lifestyle-related conditions is growing due to poor diet, physical inactivity, and increased stress levels. Antidiabetic medications can help manage lifestyle-related conditions like obesity and metabolic syndrome by improving insulin sensitivity and controlling blood sugar levels. For instance, in March 2022, the World Health Organization, a Switzerland-based intergovernmental organization, reported that around 1 billion people worldwide, 650 million adults, 340 million teenagers, and 39 million children, were obese. This number continues to rise. By 2025, an estimated 167 million adults and children will suffer health consequences due to being overweight or obese. Therefore, a rising incidence of lifestyle-related conditions is driving the antidiabetics market, with continued growth expected through 2024 and into 2028.

Get A Free Sample On The Antidiabetics Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18225&type=smp

What Are The Key Trends That Influence Antidiabetics Market Share Analysis?

Major companies operating in the antidiabetics market are developing advanced products, such as the anti-diabetic biosimilar, to improve glycemic control, reduce the risk of cardiovascular events, and offer more effective treatment options for individuals with diabetes. An anti-diabetic biosimilar is a biologically similar medication to an already approved reference drug used to treat diabetes, offering comparable safety, effectiveness, and quality. For instance, in January 2024, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, launched the first biosimilar of Liraglutide, an anti-diabetic drug. The biosimilar of the Liraglutide anti-diabetic drug, launched as Lirafit, improves glycemic control in adults with type 2 diabetes mellitus. Clinical trials have shown it lowers glycemic parameters, aids in weight loss, and enhances cardiovascular safety. As a GLP-1 receptor agonist, it boosts glucose-dependent insulin secretion and reduces inappropriate glucagon secretion. It is globally approved for managing type 2 diabetes in adults.

How Is The Global Antidiabetics Market Segmented?

1) By Drug Class: Insulin; GLP-1 Receptor Agonists; DPP- 4 Inhibitors; SGLT2 Inhibitors; Other Drug Classes,
2) By Diabetes Type: Type 1; Type 2
3) By Patient Population: Antidiabetics For Pediatrics; Antidiabetics For Adults; Antidiabetics For Geriatrics
4) By Route Of Administration: Antidiabetics Administration Through Insulin Syringes Or Insulin Pens; Antidiabetics Administration Through Insulin Pumps; Intravenous Antidiabetics Infusion; Oral Antidiabetics Administration; Other Routes Of Antidiabetics Administration
5) By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Retail Pharmacies

Read The Full Antidiabetics Market Report Here:

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

The Antidiabetics Global Market Report 2024 provides an overview of the antidiabetics market for the time series: historic years (2010 – 2021) and ten years forecast (2023 – 2032). The antidiabetics market forecast analyzes antidiabetics market size, antidiabetics market share, leading competitor and their market positions.

The Table Of Content For The Antidiabetics Market Include:

Explore Similar Reports From The Business Research Company:

Diabetic Foods Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/diabetic-foods-global-market-report

Diabetic Foot Ulcer Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/diabetic-foot-ulcer-global-market-report

Diabetic Foot Ulcer Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/diabetic-foot-ulcer-treatment-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: